title: A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration.
authors: Erasmus Medical Center, Rotterdam, The Netherlands; The Rotterdam Eye Hospital, Rotterdam, The Netherlands.
authors: P Martin
authors: PM
authors: van Hagen
authors: G Seerp
authors: GS
authors: Baarsma
authors: Christel E
authors: CE
authors: van Bilsen
authors: Robert W
authors: RW
authors: Kuijpers
authors: Jan A
authors: JA
authors: van Laar
authors: Marianne
authors: M
authors: van der Ent
authors: Paul L
authors: PL
authors: van Daele
authors: Nico J
authors: NJ
authors: Veeger
authors: Johannes R
authors: JR
authors: Vingerling
authors: Tom O
authors: TO
authors: Missotten
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D015350:Contrast Sensitivity / Q000187:drug effects / Q000502:physiology; D005122:Exudates and Transudates; D006801:Humans; D000069285:Infliximab; D009883:Ophthalmic Solutions; D014409:Tumor Necrosis Factor-alpha; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D009883:Ophthalmic Solutions; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab